Mirae Asset Global Investments Co. Ltd. Makes New Investment in 10x Genomics $TXG

Mirae Asset Global Investments Co. Ltd. purchased a new position in 10x Genomics (NASDAQ:TXG) in the 3rd quarter, HoldingsChannel.com reports. The firm purchased 49,696 shares of the company’s stock, valued at approximately $4,491,000.

A number of other large investors also recently bought and sold shares of the business. Quantinno Capital Management LP boosted its stake in 10x Genomics by 16.0% during the first quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company’s stock worth $114,892,000 after acquiring an additional 744,558 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of 10x Genomics by 34.6% during the first quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company’s stock valued at $43,357,000 after purchasing an additional 525,369 shares in the last quarter. Hsbc Holdings PLC purchased a new position in shares of 10x Genomics during the first quarter valued at approximately $5,945,000. Quantedge Capital Pte Ltd lifted its holdings in shares of 10x Genomics by 104.2% during the first quarter. Quantedge Capital Pte Ltd now owns 416,553 shares of the company’s stock valued at $8,843,000 after purchasing an additional 212,600 shares during the last quarter. Finally, Counterpoint Mutual Funds LLC bought a new stake in shares of 10x Genomics in the 3rd quarter worth approximately $11,364,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

10x Genomics Trading Up 2.1%

TXG stock traded up $1.22 during midday trading on Friday, hitting $59.28. The company’s stock had a trading volume of 4,522,645 shares, compared to its average volume of 4,178,377. The company has a market cap of $7.72 billion, a PE ratio of -114.00 and a beta of 2.03. The firm’s 50-day moving average is $73.95 and its 200-day moving average is $41.59. 10x Genomics has a 12 month low of $13.58 and a 12 month high of $102.81.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.12. The company had revenue of $150.67 million for the quarter, compared to analysts’ expectations of $147.96 million. 10x Genomics had a negative return on equity of 9.33% and a negative net margin of 12.18%. 10x Genomics’s revenue was up 1.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.22) earnings per share. Analysts expect that 10x Genomics will post -0.77 earnings per share for the current year.

Insiders Place Their Bets

In other 10x Genomics news, Director Shehnaaz Suliman sold 5,723 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $81.19, for a total transaction of $464,650.37. Following the completion of the sale, the director directly owned 23,792 shares in the company, valued at $1,931,672.48. The trade was a 19.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Serge Saxonov sold 25,000 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $81.22, for a total transaction of $2,030,500.00. Following the completion of the transaction, the chief executive officer owned 1,050,249 shares in the company, valued at $85,301,223.78. The trade was a 2.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 179,333 shares of company stock valued at $11,810,070. 8.84% of the stock is currently owned by company insiders.

More 10x Genomics News

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: 10x Genomics reported a Q3 loss of $0.15 per share, narrower than analysts’ expectations, while revenue of $150.7 million topped estimates. The company also raised its 2026 revenue outlook to $625 million–$635 million, above the roughly $620 million consensus. Q3 results
• Positive Sentiment: The company launched Sentira Single Cell, an AI-powered tool intended to simplify cell-data analysis. The product could support research adoption and create recurring revenue opportunities. Sentira launch
• Neutral Sentiment: Citigroup raised its price target from $50 to $60 but kept a neutral rating, suggesting limited upside at the cited share price. Citi target update
• Negative Sentiment: UBS cut its target from $90 to $61 and maintained a neutral rating. Meanwhile, Q3 revenue grew just 1.1% year over year and the company remains loss-making; management also cited production constraints and margin pressure, tempering optimism around stronger Atera demand. UBS target update Q3 call highlights

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on TXG shares. Stifel Nicolaus upped their price target on 10x Genomics from $50.00 to $68.00 and gave the stock a “buy” rating in a research note on Friday. Citigroup boosted their target price on 10x Genomics from $50.00 to $60.00 and gave the stock a “neutral” rating in a report on Friday. Leerink Partners increased their target price on 10x Genomics from $40.00 to $90.00 and gave the stock a “market perform” rating in a research note on Tuesday, September 29th. UBS Group reduced their price target on 10x Genomics from $90.00 to $61.00 and set a “neutral” rating for the company in a report on Friday. Finally, Barclays upped their price target on shares of 10x Genomics from $52.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Five equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, 10x Genomics has an average rating of “Hold” and an average price target of $68.07.

About 10x Genomics

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.